Archive: June 2019
IBD
Treatment De-Escalation in Patients With Inflammatory Bowel Disease
Amanda Israel, MD, Katia El Jurdi, MD, and David T. Rubin, MD
Abstract: Inflammatory bowel disease follows a relapsing and remitting course that can be augmented with the use of various pharmacologic therapies. Treatments used to induce […]
Liver Disease
Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists
Jennifer B. Miller, MD, Esteban J. Figueroa, MD, Rebecca M. Haug, MD, and Neeral L. Shah, MD
Abstract: Thrombocytopenia is a common complication of chronic liver disease and creates clinical challenges for patients who need invasive procedures. Options available to increase platelet […]
Esophagitis
Esophageal Dilation as the Primary Treatment for Eosinophilic Esophagitis
David A. Katzka, MD
G&H What are the different phenotypes of eosinophilic esophagitis, and how are they typically treated? DK It is challenging to identify the phenotypes of eosinophilic […]
IBD
Update on Pregnancy in Patients With Inflammatory Bowel Disease
Anita Afzali, MD, MPH
G&H What is the current understanding of the relationship between inflammatory bowel disease and fertility? AA Female patients whose inflammatory bowel disease (IBD) is under […]
Endoscopy
EUS-Guided Gastroenterostomy Vs Duodenal Stenting for the Palliation of Malignant Gastric Outlet Obstruction
Mouen A. Khashab, MD
G&H What methods are available to palliate patients with malignant gastric outlet obstruction? MK Surgical gastrojejunostomy, duodenal stenting, and endoscopic ultrasound (EUS)-guided gastroenterostomy are the […]
HCC
Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection
Jordan Feld, MD, MPH
G&H What is the current understanding of the relationship between hepatocellular carcinoma and hepatitis C virus infection? JF Hepatitis C virus (HCV) is a carcinogenic […]
Gastro-Hep News
Gastro-Hep News
Samantha Alleman
US Food and Drug Administration Approves Teduglutide for Pediatric Patients With Short Bowel Syndrome On May 17, 2019, the US Food and Drug Administration (FDA) expanded […]
Hepatology
Emerging Research on MGL-3196 for the Treatment of Nonalcoholic Steatohepatitis
Zobair Younossi, MD, MPH
G&H What is the mechanism of action of MGL-3196? ZY MGL-3196 (Madrigal Pharmaceuticals) is a thyroid hormone receptor β agonist. Thyroid hormone receptors can be […]
Letter From the Editor
Letter From the Editor: De-Escalation of Therapy for Inflammatory Bowel Disease
Gary R. Lichtenstein, MD, AGAF, FACP, FACG
When and how should therapy be de-escalated in patients with Crohn’s disease and ulcerative colitis? In this month’s issue of Gastroenterology & Hepatology, Dr Amanda Israel, […]